Related Experiment Videos
Thyroid stimulating hormone receptor antibody in thyroid diseases
N Vadivelu1, D C Stephen, A S Kanagasabapathy
1Department of Clinical Biochemistry, Christian Medical College & Hospital, Vellore.
The Indian Journal of Medical Research
|August 1, 1990
Summary
Thyroid stimulating hormone receptor antibody (TRA) levels were measured in various groups. In Graves' disease patients, TRA levels decreased with carbimazole treatment, correlating with recovery.
Area of Science:
- Endocrinology
- Immunology
- Thyroidology
Background:
- Thyroid stimulating hormone receptor antibody (TRA) is a key marker for Graves' disease.
- Assessing TRA levels aids in understanding disease activity and treatment response.
Purpose of the Study:
- To estimate TRA as a measure of TSH binding inhibitory immunoglobulin (TBII).
- To evaluate TRA levels in patients with Graves' disease undergoing carbimazole treatment.
- To correlate TRA levels with clinical and biochemical recovery.
Main Methods:
- Radioimmunoassay (RIA) was used to measure TRA levels.
- Thyroid function tests including total thyroxine (T4), free thyroxine concentration (FTC), and TSH were performed.
- Study included controls, Graves' disease patients, toxic nodular goitre, euthyroid exophthalmos, and neonates of thyrotoxic mothers.
Main Results:
- All controls had undetectable TRA levels.
- 87% of Graves' disease patients were TRA positive within 3 months of carbimazole therapy.
- Serial studies showed a decline in TRA levels in 7 out of 8 Graves' disease patients, coinciding with recovery.
Conclusions:
- TRA estimation is valuable for monitoring Graves' disease.
- Declining TRA levels correlate with successful treatment and biochemical recovery in Graves' disease patients.